CENTOGENE NV (CNTG)
NL0014040206 - Common Stock
CNTG gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 109 industry peers in the Health Care Providers & Services industry. CNTG may be in some trouble as it scores bad on both profitability and health. CNTG does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
CNTG had negative earnings in the past year.
In the past year CNTG has reported a negative cash flow from operations.
CNTG had negative earnings in each of the past 5 years.
CNTG had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -46.05%, CNTG is doing worse than 85.34% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.05% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-43.71%
ROA(5y)-32.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 36.46%, CNTG is in the better half of the industry, outperforming 63.79% of the companies in the same industry.
In the last couple of years the Gross Margin of CNTG has declined.
CNTG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 36.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.22%
GM growth 5Y-6.4%
2. Health
2.1 Basic Checks
CNTG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CNTG has more shares outstanding
The number of shares outstanding for CNTG has been increased compared to 5 years ago.
CNTG has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.03, we must say that CNTG is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CNTG (-1.03) is worse than 81.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.03 |
ROIC/WACCN/A
WACC7.5%
2.3 Liquidity
A Current Ratio of 1.02 indicates that CNTG should not have too much problems paying its short term obligations.
CNTG has a Current ratio of 1.02. This is in the lower half of the industry: CNTG underperforms 68.10% of its industry peers.
A Quick Ratio of 0.96 indicates that CNTG may have some problems paying its short term obligations.
CNTG's Quick ratio of 0.96 is on the low side compared to the rest of the industry. CNTG is outperformed by 62.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.96 |
3. Growth
3.1 Past
The earnings per share for CNTG have decreased by -6.92% in the last year.
CNTG shows a small growth in Revenue. In the last year, the Revenue has grown by 2.25%.
CNTG shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.70% yearly.
EPS 1Y (TTM)-6.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.92%
Revenue 1Y (TTM)2.25%
Revenue growth 3Y8.07%
Revenue growth 5Y3.7%
Sales Q2Q%254.74%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y39.38%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year22.37%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
CNTG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CNTG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
CNTG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CENTOGENE NV
NASDAQ:CNTG (8/7/2024, 8:06:53 PM)
After market: 0.351 +0.03 (+8%)0.325
-0.02 (-6.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.09%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap8.97M
Analysts82.86
Price Target1.53 (370.77%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.17 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.39
EYN/A
EPS(NY)-1.09
Fwd EYN/A
FCF(TTM)-1.36
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS1.94
BVpS-1.01
TBVpS-1.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.05% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 36.46% | ||
| FCFM | N/A |
ROA(3y)-43.71%
ROA(5y)-32.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.22%
GM growth 5Y-6.4%
F-Score2
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 29.95% | ||
| Cap/Sales | 4.7% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z | -1.03 |
F-Score2
WACC7.5%
ROIC/WACCN/A
Cap/Depr(3y)25.62%
Cap/Depr(5y)60.29%
Cap/Sales(3y)7.53%
Cap/Sales(5y)16.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.92%
EPS Next Y39.38%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)2.25%
Revenue growth 3Y8.07%
Revenue growth 5Y3.7%
Sales Q2Q%254.74%
Revenue Next Year22.37%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.85%
OCF growth 3YN/A
OCF growth 5YN/A